NanoBio, a biopharmaceutical company focused on the development and commercialization of vaccines and anti-infective treatments, and a Wolverine Venture Fund portfolio company, presented new data on its Herpes 2 (HSV-2) vaccine at this year’s National Foundation for Infectious Diseases’ 17th Annual Conference on Vaccine Research (ACVR). This is a great milestone for NanoBio–data from pre-clinical guinea pig studies demonstrated the ability of NanoBio’s intranasal NE vaccine to enhance protection against HSV-2 as compared to leading intramuscular vaccine candidates.
Looking ahead, the company plans to conduct additional studies in guinea pigs to optimize dosing and expects to advance into clinical testing in the near future. Check out NanoBio’s news release to learn more about the results.